SORAFENIB
Bayer receives Canadian approval for Nexavar to treat differentiated thyroid cancer
Health Canada has approved Bayer’s Nexavar (sorafenib tablets) for treatment of patients with locally advanced or metastatic, progressive, differentiated (papillary/follicular/Hurthle cell) thyroid carcinoma, refractory to radioactive iodine.
Nexavar’s approval in Canada is supported by a positive outcome from the Phase III DECISION (‘stuDy of sorafEnib in loCally advanced or metastatIc patientS with radioactive Iodine refractory thyrOid caNcer’) trial.
FOOTBALL BRAZIL 2014
Filed under: canada, cancer Tagged: BAYER, CANADA, Canadian approval, health canada, Nexavar, radioactive iodine, Sorafenib, thyroid cancer
